CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

The partnership will allow Shire to utilize ICON’s central labs’ extensive test menu from its global network of laboratories. As partner in clinical development, ICON also will provide Shire with a full range of services, including clinical trial monitoring, ethics and regulatory submissions, site and country feasibility, medical management and medical data review, site and study team support and project management.

“We are proud that Shire Specialty Pharmaceuticals has selected Icon as a global partner and it is yet another endorsement of Icon’s expertise in operating under strategic partnership models,” said Ciaran Murray, CEO of ICON.